FARS2缺陷通过破坏线粒体稳态及质量控制导致心肌病
研究通过全外显子测序在肥厚型心肌病患者中鉴定出7个未报道的FARS2变异,并构建小鼠、斑马鱼及细胞模型,发现FARS2缺陷通过阻断mt-tRNAPhe氨酰化、抑制线粒体蛋白合成,加速线粒体过度碎片化并干扰线粒体自噬,导致心肌肥厚、心衰及线粒体功能障碍,干预线粒体质量控制可改善表型。
要点
- FARS2是肥厚型心肌病潜在的新致病基因,检出7个未报道变异。
- FARS2缺陷通过损害线粒体翻译和自噬导致心肌病表型。
- 干预线粒体质量控制可减轻FARS2缺陷相关心脏功能障碍。
核心结论
- FARS2缺陷通过破坏线粒体稳态及质量控制导致心肌病,为分子诊断和治疗提供新方向。
研究设计与样本
- 研究对肥厚型心肌病患者行全外显子测序、Sanger测序及分子对接鉴定FARS2变异。
- 构建心脏特异性Fars2条件突变(p.R415L)或敲除小鼠、fars2敲低斑马鱼及敲低新生大鼠心室肌细胞模型。
主要发现
- 在肥厚型心肌病患者中鉴定出7个未报道的FARS2变异。
- 心脏特异性Fars2缺陷小鼠表现为心脏肥厚、左室扩张、进行性心衰伴心肌和线粒体功能障碍及寿命缩短。
- 杂合心脏特异性Fars2R415L小鼠在4周龄时出现心脏肥厚倾向,伴心肌功能障碍。
- fars2敲低斑马鱼出现心包水肿和心力衰竭。
- FARS2缺陷直接阻断mt-tRNAPhe氨酰化、抑制线粒体蛋白合成,加速线粒体过度碎片化并干扰线粒体自噬。
临床怎么用
- 对部分肥厚型心肌病患者可考虑FARS2基因筛查以明确分子诊断。
- 针对线粒体质量控制系统的干预可能成为FARS2相关心肌病的治疗选项。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Hypertrophic cardiomyopathy (HCM) is a common heritable heart disease. Although HCM has been reported to be associated with many variants of genes involved in sarcomeric protein biomechanics, pathogenic genes have not been identified in patients with partial HCM. FARS2 (the mitochondrial phenylalanyl-tRNA synthetase), a type of mitochondrial aminoacyl-tRNA synthetase, plays a role in the mitochondrial translation machinery. Several variants of FARS2 have been suggested to cause neurological disorders; however, FARS2-associated diseases involving other organs have not been reported. We identified FARS2 as a potential novel pathogenic gene in cardiomyopathy and investigated its effects on mitochondrial homeostasis and the cardiomyopathy phenotype. METHODS: FARS2 variants in patients with HCM were identified using whole-exome sequencing, Sanger sequencing, molecular docking analyses, and cell model investigation. Fars2 conditional mutant (p.R415L) or knockout mice, fars2-knockdown zebrafish, and Fars2-knockdown neonatal rat ventricular myocytes were engineered to construct FARS2 deficiency models both in vivo and in vitro. The effects of FARS2 and its role in mitochondrial homeostasis were subsequently evaluated using RNA sequencing and mitochondrial functional analyses. Myocardial tissues from patients were used for further verification. RESULTS: We identified 7 unreported FARS2 variants in patients with HCM. Heart-specific Fars2-deficient mice presented cardiac hypertrophy, left ventricular dilation, progressive heart failure accompanied by myocardial and mitochondrial dysfunction, and a short life span. Heterozygous cardiac-specific Fars2R415L mice displayed a tendency to cardiac hypertrophy at age 4 weeks, accompanied by myocardial dysfunction. In addition, fars2-knockdown zebrafish presented pericardial edema and heart failure. FARS2 deficiency impaired mitochondrial homeostasis by directly blocking the aminoacylation of mt-tRNAPhe and inhibiting the synthesis of mitochondrial proteins, ultimately contributing to an imbalanced mitochondrial quality control system by accelerating mitochondrial hyperfragmentation and disrupting mitochondrion-related autophagy. Interfering with the mitochondrial quality control system using adeno-associated virus 9 or specific inhibitors mitigated the cardiac and mitochondrial dysfunction triggered by FARS2 deficiency by restoring mitochondrial homeostasis. CONCLUSIONS: Our findings unveil the previously unrecognized role of FARS2 in heart and mitochondrial homeostasis. This study may provide new insights into the molecular diagnosis and prevention of heritable cardiomyopathy as well as therapeutic options for FARS2-associated cardiomyopathy.
引用
- Li B, Liu F, Chen X, et al. FARS2 Deficiency Causes Cardiomyopathy by Disrupting Mitochondrial Homeostasis and the Mitochondrial Quality Control System. Circulation. 2024. PMID: 38362779. doi:10.1161/CIRCULATIONAHA.123.064489
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。